Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 66c

Castle Biosciences Inc. (NASDAQ: CSTL) reported Q2 EPS of $0.15, $0.66 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $86.19 million versus the consensus estimate of $71.43 million.

For earnings history and earnings-related data on Castle Biosciences Inc. (CSTL) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c